TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
出版年份 2014 全文链接
标题
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
作者
关键词
-
出版物
BLOOD
Volume 124, Issue 17, Pages 2705-2712
出版商
American Society of Hematology
发表日期
2014-09-16
DOI
10.1182/blood-2014-06-582809
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
- (2014) Amer M. Zeidan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
- (2014) Cecile Bally et al. LEUKEMIA RESEARCH
- Clinical and biological implications of driver mutations in myelodysplastic syndromes
- (2013) E. Papaemmanuil et al. BLOOD
- Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
- (2013) R. Z. Mahfouz et al. CLINICAL CANCER RESEARCH
- NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes
- (2013) D M Murphy et al. LEUKEMIA
- Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
- (2013) M J Walter et al. LEUKEMIA
- Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
- (2013) A Valencia et al. LEUKEMIA
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
- (2013) T Haferlach et al. LEUKEMIA
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes
- (2013) Y. Saunthararajah Hematology-American Society of Hematology Education Program
- ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
- (2012) Omar Abdel-Wahab et al. CANCER CELL
- Effects ofTET2mutations on DNA methylation in chronic myelomonocytic leukemia
- (2012) Jumpei Yamazaki et al. Epigenetics
- Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
- (2012) Rafael Bejar et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response
- (2012) Massimo Breccia et al. LEUKEMIA & LYMPHOMA
- Clonal Architecture of Secondary Acute Myeloid Leukemia
- (2012) Matthew J. Walter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells
- (2012) Hiroyoshi Kunimoto et al. Scientific Reports
- Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies
- (2011) Z. Li et al. BLOOD
- Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation
- (2011) Kelly Moran-Crusio et al. CANCER CELL
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Frequent pathway mutations of splicing machinery in myelodysplasia
- (2011) Kenichi Yoshida et al. NATURE
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- (2011) Mark A DePristo et al. NATURE GENETICS
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
- (2011) Taichun Qin et al. PLoS One
- Fast and accurate long-read alignment with Burrows–Wheeler transform
- (2010) Heng Li et al. BIOINFORMATICS
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
- (2010) Myunggon Ko et al. NATURE
- Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
- (2009) M. Jadersten et al. HAEMATOLOGICA
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
- (2009) Lanlan Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes
- (2009) Pierre Fenaux et al. LEUKEMIA RESEARCH
- Demethylating agents in myeloid malignancies
- (2008) Guillermo Garcia-Manero CURRENT OPINION IN ONCOLOGY
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
- (2008) Carlo Stresemann et al. INTERNATIONAL JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now